Abbonarsi

Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma - 24/02/22

Doi : 10.1016/j.diii.2022.01.006 
Shamar Young a, , Tina Sanghvi b, Sandeep Sharma a, Cameron Richardson a, Nathan Rubin a, Masters Richards a, Donna D'Souza a, Siobhan Flanagan a, Jafar Golzarian a
a University of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA 
b Minneapolis VA Medical Center, Department of Radiology, MN, 55417, USA 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Highlights

A significant proportion of patients with hepatocellular carcinoma who achieve complete radiologic response following transarterial chemoembolization will have local recurrence.
Variables such as liver function prior to transarterial chemoembolization and cause of underlying cirrhosis may predict local recurrence rates following complete response.
This study suggests that transarterial chemoembolization should be considered palliative and emphasizes the importance of long term follow up by interventional radiologists after treatment.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Purpose

The purpose of this study was to determine the local progression rate and identify factors that may predict local progression, in patients who achieve a complete response (CR) radiologically after undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).

Materials and methods

One-hundred-forty-seven patients, who achieved CR of 224 HCCs after TACE, were retrospectively reviewed. There were 109 men and 38 women with a mean age of 61.6 ± 6.8 (SD) years (range: 45.4–86.9 years). Logistic mixed-effects and Cox regression models were used to evaluate associations between clinical factors and local progression.

Results

A total of 75 patients (75/147; 51%) and 99 (99/224,44.2%) lesions showed local progression at a median of 289.5 days (Q1: 125, Q3: 452; range: 51–2245 days). Pre-treatment, international normalization ratio (INR) (1.17 ± 0.15 [SD] vs. 1.25 ± 0.16 [SD]; P <0.001), model for end-stage liver disease (9.4 ± 2.6 [SD] vs. 10.6 ± 3.2 [SD]; P = 0.010) and Child-Pugh score (6 ± 1 [SD] vs. 6.4 ± 1.3 [SD]; P = 0.012) were significantly lower while albumin serum level (3.4 ± 0.62 [SD] vs. 3.22 ± 0.52 [SD]; P = 0.033) was significantly greater in those who showed local progression as compared to those who did not. In terms of local-recurrence free survival, the number of TACE treatments (hazard ratio [HR]: 2.05 [95% CI: 1.57–2.67]; P<0.001), INR (HR: 0.13 [95% CI: 0.03–0.61]; P = 0.010) and type of TACE (P = 0.003) were significant. Patients with local progression on any tumor did not differ from those who did in terms of overall survival (P = 0.072), however, were less likely to be transplanted (20/75, 26.7%) than those who did not (33/72; 36.1%) (P = 0.016).

Conclusion

A significant number of patients who achieve CR of HCC after TACE have local progression. This emphasizes the importance of long-term follow up.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : End stage liver disease, Interventional radiology, Hepatocellular carcinoma, Survival studies, Therapeutic chemoembolization


Mappa


© 2022  Société française de radiologie. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 103 - N° 3

P. 143-149 - marzo 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Structured and shared MRI staging lexicon and report of rectal cancer: A consensus proposal by the French Radiology Group (GRERCAR) and Surgical Group (GRECCAR) for rectal cancer
  • Stephanie Nougaret, Pascal Rousset, Kirsten Gormly, Oliver Lucidarme, Serge Brunelle, Laurent Milot, Cécile Salut, Franck Pilleul, Lionel Arrivé, Constance Hordonneau, Guillaume Baudin, Philippe Soyer, Vanessa Brun, Valérie Laurent, Celine Savoye-Collet, Iva Petkovska, Jean Pierre Gerard, Eric Rullier, Eddy Cotte, Philippe Rouanet, Regina G.H. Beets-Tan, Nora Frulio, Christine Hoeffel
| Articolo seguente Articolo seguente
  • External validation of a commercially available deep learning algorithm for fracture detection in children
  • Michel Dupuis, Léo Delbos, Raphael Veil, Catherine Adamsbaum

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.